Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report) saw a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 4,198,000 shares, an increase of 71.7% from the July 30th total of 2,444,582 shares. Based on an average daily trading volume, of 3,300 shares, the days-to-cover ratio is presently 1,272.1 days.
Genscript Biotech Stock Performance
GNNSF stock opened at C$4.65 on Wednesday. The company’s fifty day simple moving average is C$2.46 and its 200 day simple moving average is C$1.88. Genscript Biotech has a 12-month low of C$1.30 and a 12-month high of C$5.00.
Genscript Biotech Company Profile
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Recommended Stories
- Five stocks we like better than Genscript Biotech
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
